Curia Global

Custom API Manufacturing, Fermentation, Finished Dosage Form, High Potency, Lipid Nanoparticle, Rare / Orphan, Stability & Release Testing, Sterile Fill Finish, APIs & Intermediates, Fine Chemicals

Discovery - Biology, Lead Optimization, Libraries, Synthetic & Medicinal ChemistryDevelopment - Chemical Process R&D, Fermentation, Formulation Development, High Potency, Kilo Lab & Small Scale Manufacturing, Lipid Nanoparticle, Method Development/Material Science, Rare/Orphan, Separation Scien...

Curia offers end-to-end services for antibodies, proteins, enzymes, and mRNA vaccines and therapeutics.

Curia Small Molecule offers a wide array of integrated services and approaches - from design and optimization, to manufacturing, to analytical support facilities around the world.

Curia offers an extensive portfolio of 150+ generica APIs, covering multiple therapeutic areas. We offer more than 30 years of generic API manufacturing experience to our pharmaceutical partners.

Supporting you from early stage development to commercial manufacturing, our proven track record with parenteral formulations demonstrates our ability to be your partner for the entire product life-cycle.

Albany, NY- October 27, 2025 – Curia, a leading global research, development and manufacturing organization, today announced the completion of a $4 million investment to upgrade its two API aseptic suites in Valladolid, Spain. The investment aligns with the latest EU GMP Annex 1 standards and reinforces Curia’s longstanding commitment to regulatory excellence and product quality. Annex 1 provides general guidance for the design and control of facilities, equipment, systems, and procedures used for the manufacture of all sterile products, applying the principles of Quality Risk Management (QRM) to prevent microbial, particulate, and endotoxin contamination in the final product.

Curia Biologic Service

The Glasgow, UK, site is well known throughout the industry for its more than 25 years of experience with formulation, lyophilization development and sterile fill-finish capabilities, including ADCs and other highly potent products. The current expansion is expected to be completed by early 2027. The investment will add an Annex 1 compliant isolator-based vial filling line and lyophilizer. Once complete, Glasgow will be able to fill batches up to 20,000 vials and will be well‑positioned to support future small‑scale commercial fills.

API Catalog

Sterile Drug Product Fact Sheet

Curia corporate overview.

Curia API Catalog

Curia Biologics Discovery fact sheet

Curia Small Molecule Fact Sheet

Curia Sterile Drug Product Fact Sheet